Frankfurt
26.06.25 | 08:03
1,482 Euro
-7,61 % -0,122
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,576 | 1,574 | 14:25 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CROSSJECT Aktie jetzt für 0€ handeln | |||||
| Di | CROSSJECT announces a successful capital increase of €5.7 million following full exercise of the extension clause | 5 | GlobeNewswire (USA) | ||
| 11.06. | CROSSJECT advances on the development of ZEPIZURE Junior, its solution for epilepsy crises in children | 73 | GlobeNewswire (Europe) | Press release CROSSJECT advances on the development of ZEPIZURE® Junior, its solution for epilepsy crises in children Announces the effective calibration of ZENEO® for the use of ZEPIZURE® in the... ► Artikel lesen | |
| 04.06. | CROSSJECT: Launch of a capital increase with preferential subscription rights for nearly 5 million euros | 1 | GlobeNewswire (USA) | ||
| 03.06. | Maxim Group initiates the coverage of the CROSSJECT share with a BUY recommendation and a target price of €4.00 | 51 | GlobeNewswire (Europe) | Press release Maxim Group initiates the coverage of the CROSSJECT share with a BUY recommendation and a target price of €4.00 Dijon, France 03 June 2025 (07.30 CET) -- CROSSJECT (ISIN: FR0011716265... ► Artikel lesen | |
| 27.05. | CROSSJECT implements new manufacturing module to scale-up the ZENEO Factory 's versatility and capacity in anticipation of full product pipeline deployment | 3 | GlobeNewswire (USA) | ||
| 20.05. | CROSSJECT prepares for the launch of a capital increase with preferential subscription rights of around 5 million euros in preparation for commercial and production activities linked to EUA approval | 2 | GlobeNewswire (USA) | ||
| 15.05. | CROSSJECT's ZENEO needle-free autoinjector consistently matches depth of traditional intramuscular injections and exceeds the standards needle length of currently utilized auto-injectors | 93 | GlobeNewswire (Europe) | Press Release CROSSJECT's ZENEO® needle-free auto-injector consistently matches depth of traditional intramuscular injections and exceeds the standards needle length of currently utilized auto-injectors... ► Artikel lesen | |
| 07.05. | CROSSJECT provides updates on the EUA filing of ZEPIZURE | 2 | GlobeNewswire (USA) | ||
| 27.03. | CROSSJECT reports financial results for 2024 | 149 | GlobeNewswire (Europe) | Press Release CROSSJECT reports financial results for 2024 Continued satisfactory production of regulatory batches with a view to filing in Q2 2025.Recruitment of Tony Tipton as Chief Operating Officer... ► Artikel lesen | |
| 25.03. | CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO adrenal insufficiency program | 192 | GlobeNewswire (Europe) | Press Release CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program CROSSJECT enhanced its collaboration with Eton Pharmaceuticals,... ► Artikel lesen | |
| 18.03. | CROSSJECT achieves key ZEPIZURE manufacturing batch stability milestones | 1 | GlobeNewswire (USA) | ||
| 12.02. | Crossject announces the reappointment of Patrick Alexandre and Isabelle Liebschutz as members of new, streamlined Executive Board | 175 | GlobeNewswire (Europe) | Dijon, FRANCE, February 12, 2025 - 0730 (CET) - Crossject (ISIN: FR0011716265; Euronext Growth: ALCJ), a specialty pharma company developing medicines harnessing its unique, award-winning needle-free... ► Artikel lesen | |
| 19.12.24 | Crossject confirms ZEPIZURE supply chain readiness with another successful ISO audit for Quality Management System | 140 | GlobeNewswire (Europe) | Crossject successfully passes another ISO 13485 audit for sites in Dijon and Gray (France)Company is ramping up supply chain to prepare for commercialization in U.S. Dijon, France, December 19, 2024... ► Artikel lesen | |
| 22.10.24 | Crossject reports strong manufacturing progress with its epilepsy rescue therapy ZEPIZURE ahead of filing U.S. Emergency Use Authorization | 157 | GlobeNewswire (Europe) | Product batch announced in July yielded new regulatory stability data. These results will directly support the requested 6-month stability data in the first quarter of 2025Crossject expects to file... ► Artikel lesen | |
| 23.09.24 | Crossject reports financial results and business highlights for the first six months of 2024 | 279 | GlobeNewswire (Europe) | Available cash €5.95 million, up from €2.3 million on December 31, 2023Reports stable investments in R&D and consolidation of operating income from BARDACompany on track to successfully file for the... ► Artikel lesen | |
| 19.08.24 | Crossject appoints Tony Tipton as U.S. Chief Operating Officer in Preparation for Commercialization of ZEPIZURE Epilepsy Rescue Treatment | 307 | GlobeNewswire (Europe) | Press Release Crossject appoints Tony Tipton as U.S. Chief Operating Officer in Preparation for Commercialization of ZEPIZURE® Epilepsy Rescue Treatment Experienced executive to lead preparations... ► Artikel lesen | |
| 18.07.24 | Crossject achieves key ZEPIZURE manufacturing milestone | 210 | GlobeNewswire (Europe) | Successful completion of an additional Registration Batch of ZEPIZURE® at new manufacturing siteMilestone complements the satisfying results from previous batches under stability studies, and is... ► Artikel lesen | |
| 10.07.24 | Crossject is awarded a 6.9 million euros financing from the French Government, as part of the France 2030 innovation plan, to accelerate the development of ZENEO Epinephrine | 221 | GlobeNewswire (Europe) | Key contribution to the acceleration of the development of ZENEO® EpinephrineFinancial support includes mainly grants, as well as subsidized loansFrance 2030 Plan dedicated to supporting French companies... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS | 42,020 | +0,17 % | EQS-PVR: Fresenius SE & Co. KGaA: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
20.06.2025 /... ► Artikel lesen | |
| INTUITIVE SURGICAL | 445,35 | -0,46 % | Intuitive Surgical Aktie: Sondermeldung sorgt für starke Verunsicherung. Das ist der Grund und so müssen Anleger heute handeln! | ||
| HIMS & HERS HEALTH | 35,880 | +0,96 % | Entspannungsrallye voraus - TUI, IBM, Hims & Hers, Nike, Tesla, Super Micro Computer | Der DAX hat die Eskalation im Konflikt zwischen dem Iran und den USA recht gut weggesteckt. Gestern schloss er leicht im Minus. Heute gibt es die berechtigte Hoffnung, dass der DAX zum Start deutlich... ► Artikel lesen | |
| SERNOVA BIOTHERAPEUTICS | 0,105 | -2,78 % | Research Capital analyst Andre Uddin keeps "Speculative Buy" rating on Sernova Biotherapeutics | ||
| FAMICORD | 4,180 | 0,00 % | Original-Research: FamiCord AG (von Montega AG): Kaufen | Original-Research: FamiCord AG - von Montega AG 06.06.2025 / 17:08 CET/CEST Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group. Für den Inhalt der Mitteilung... ► Artikel lesen | |
| GERATHERM MEDICAL | 3,340 | +5,70 % | Geratherm Medical AG: GJ24 war herausfordernd, vorsichtige Prognose für GJ25; mwb research bekräftigt KAUFEN | Die Ergebnisse von Geratherm für das Geschäftsjahr 2024 zeigten einen Umsatzrückgang von 33% auf 14,0?Mio.?EUR, was in erster Linie auf deutliche Rückgänge in den Bereichen Healthcare Diagnostics und... ► Artikel lesen | |
| ALIGN TECHNOLOGY | 160,70 | +0,09 % | Align Technology, Inc. (ALGN): A Bull Case Theory | ||
| NUGEN MEDICAL DEVICES | 0,034 | +3,64 % | NuGen Medical Devices - Lillys Geschichte: Ein Teenager aus Nordkanada… | ||
| PLUS THERAPEUTICS | 0,325 | 0,00 % | Plus Therapeutics Inc.: Plus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM for the Treatment of Childhood Brain Cancer | Phase 1/2a clinical trial currently supported by a $3.0 million grant from the U.S. Department of Defense Trial will enroll children with high grade glioma and ependymoma HOUSTON, June 25, 2025... ► Artikel lesen | |
| CARDINAL HEALTH | 140,55 | +0,07 % | Cardinal Health stock hits all-time high at 166.3 USD | ||
| RESMED | 220,90 | -0,14 % | ResMed-Aktie: Kurs steigt nur geringfügig (220,1782 €) | An der US-amerikanischen Börse ist die Aktie von ResMed zur Stunde unauffällig. Der jüngste Kurs betrug 254,22 US-Dollar. Kaum verändert im Vergleich zu der Schlussnotierung vom Vortag zeigt sich aktuell... ► Artikel lesen | |
| DAVITA | 120,85 | +0,33 % | 3 Takeaways From DaVita CEO Javier Rodriguez on the Future of Health Technology | NORTHAMPTON, MA / ACCESS Newswire / June 20, 2025 / Health care conversations have outgrown the concept of transformation; what we need now is a revolution, driven by the capabilities of cutting-edge... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 46,900 | -0,15 % | UBS stuft Siemens Healthineers auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Siemens Healthineers mit einem Kursziel von 50 Euro auf "Neutral" belassen. Die Bayern gehörten im europäischen Medtech-Bereich... ► Artikel lesen | |
| GENEDX | 88,94 | 0,00 % | GeneDx price target raised to $105 from $80 at Jefferies on AAP update | ||
| CARL ZEISS MEDITEC | 55,75 | -2,71 % | Aktienmarkt: Aktie von Carl Zeiss Meditec kann sich nicht behaupten (56,30 €) | Im deutschen Wertpapierhandel liegt die Carl Zeiss Meditec-Aktie gegenwärtig im Minus. Das Wertpapier kostete zuletzt 56,30 Euro. Ein Wertverlust in Höhe von 1,75 Euro müssen derzeit die Aktionäre von... ► Artikel lesen |
Das Unternehmen CROSSJECT SA kann der Branche Gesundheitswesen zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,122 (-7,61 %) liegt der Kurs bei 1,482 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CROSSJECT SA finden Sie auf Wallstreet Online.